
Micro-Invasive Glaucoma Surgery (MIGS)
Clinical Determination and Indication Number: 00047
Original Effective Date: May 1, 2025
Last Review Date: August 1, 2025
I. Disclaimer
This document is intended to be used as a reference for non-VA providers and is not intended to replace clinical judgment when determining care pathways. These guidelines do not guarantee benefits or constitute medical advice.
II. Clinical Determinations and Indications
- Indications
Microinvasive glaucoma surgery (MIGS) consists of a variety of procedures and devices that are indicated for the treatment of glaucoma and include trabecular meshwork bypass by stent placement, trabecular meshwork bypass by tissue excision (trabeculotomy/ab interno trabeculectomy), aqueous outflow through Schlemm’s Canal (canaloplasty), and aqueous shunt through subconjunctival space. Indications and clinical criteria are described below. The VA follows FDA approved indications for medical devices.- Indications for Trabecular Meshwork Bypass by Stent Placement
Trabecular meshwork micro-bypass stents are indicated for the treatment of glaucoma and will be considered medically necessary when ALL the following criteria are met while following FDA and manufacturers recommendations for a given device:
- Veteran has mild to moderate open-angle glaucoma confirmed with gonioscopy
- Veteran is currently being treated with an ocular hypotensive medication or has difficulty adhering to medical treatment regimen
- Indications for Trabecular Meshwork Bypass by Tissue Excision
(Trabeculotomy/Ab Interno Trabeculectomy)Trabeculotomy is indicated for the treatment of glaucoma and will be considered medically necessary when ALL the following criteria are met while following FDA and manufacturers recommendations for a given device:
- Veteran has at least mild to severe open-angle glaucoma confirmed with gonioscopy
- May be considered for Veterans with angle closure glaucoma
- Intraocular pressure (IOP) is not responsive to maximum tolerated medical therapy or there is documentation of why this procedure may work for the Veteran
- Veteran has at least mild to severe open-angle glaucoma confirmed with gonioscopy
- Indications for Enhancing Aqueous Outflow Through Schlemm’s Canal (Canaloplasty)
Canaloplasty is indicated for the treatment of glaucoma and will be considered medically necessary when ALL the following criteria are met while following FDA and manufacturers recommendations for a given device:
- Veteran has open-angle glaucoma confirmed with gonioscopy
- Intraocular pressure (IOP) is not responsive to maximum tolerated medical therapy
- Indications for Trabecular Meshwork Bypass by Tissue Excision (Trabeculotomy/Ab Interno Trabeculectomy)
Trabeculotomy is indicated for the treatment of glaucoma and will be considered medically necessary when ALL the following criteria are met while following FDA and manufacturers recommendations for a given device:
- Veteran has open-angle glaucoma confirmed with gonioscopy
- Intraocular pressure (IOP) is not responsive to maximum tolerated medical therapy
- Indications for Trabecular Meshwork Bypass by Stent Placement
- Limitations/Exclusions
Microinvasive glaucoma surgery (MIGS) is not indicated for uses that are not FDA approved or fall outside the manufacturer’s recommendations. For all indications not listed in section II.a. of this document, MIGS is considered not medically necessary due to insufficient evidence of efficacy and safety.
- Description of Treatment
Microinvasive glaucoma surgery (MIGS), also known as internal filtration surgery, is a group of surgical interventions that share four characteristics:- High safety profile with lower risk of serious complications
- Minimal disruption of normal anatomy
- Efficacious in lowering IOP
- Ease of use for patients and physicians with rapid recovery and minimal additional downtime
There are four FDA approved approaches to lowering IOP by targeting the normal flow of fluid in the eye. Each approach is described below.
- Trabecular Meshwork Bypass by Stent Placement
- Stents are implanted into the trabecular meshwork which is in the anterior chamber angle of the eye. The body of the stent sits in Schlemm’s Canal while a flange in the anterior chamber allows aqueous entrance into the stent and canal.
- Trabecular Meshwork Bypass through Tissue Excision (Trabeculotomy/Ab Interno Trabeculectomy)
- Trabeculotomy/ab interno trabeculectomy involves cutting through the trabecular meshwork to create an opening into the Schlemm’s Canal and enhance the natural drainage system from the anterior chamber.
- Enhancing Aqueous Outflow Through Schlemm’s Canal (Canaloplasty)
- Canaloplasty is completed through cannulation and dilatation of Schlemm’s Canal.
- Aqueous Shunt through the Subconjunctival Space
- The Xen gel stent is a small single piece lumen that is implanted to create a channel from the anterior chamber to the subconjunctival space. This procedure creates an alternative drainage flow for aqueous fluid.
Note: These procedures must be performed by a qualified licensed physician (MD or DO) who has completed a residency and/or fellowship program that includes the use of skills necessary to perform these procedures. In addition, the surgeon will perform appropriate follow-up that adheres to the American Academy of Ophthalmology Preferred Practice Pattern guidelines for glaucoma.
III. Background and Supporting Information
The following information is for reference purposes only in accordance with the medical benefits package outlined in 38 C.F.R. § 17.38 (b). Each subsection supports VA’s determinations for medical necessity and alignment with generally accepted standards of medical practice.
- Background Information
Glaucoma refers to a group of chronic diseases that damage the optic nerve. It is one of the leading causes of visual disability and irreversible blindness in the world. If left untreated or insufficiently treated, can lead to irreversible vision loss and blindness. The key objectives in the management of glaucoma are to maximize quality of life, preserve remaining visual function, and minimize further vision loss.The eye consistently produces aqueous fluid, which is a clear liquid inside the eye. When new aqueous fluid flows into the eye, the same amount should drain or flow out of the eye through the aqueous fluid outflow pathway. The natural outflow pathway contains the trabecular meshwork, and the distal system, which includes Schlemm’s Canal, collector channels, and the aqueous venous system. Glaucoma develops when the optic nerve is damaged, often when the intraocular pressure (IOP) is above the average range, but optic nerve damage can also occur when the IOP is within the normal range. In some cases, the drainage of the aqueous fluid is not efficiently drained, so aqueous fluid builds up and causes IOP to increase. The increased IOP may result in permanent damage to the optic nerve ultimately leading to progressive, painless vision loss. By lowering the IOP, the rate of vision loss decreases. IOP can be lowered by increasing the outflow of aqueous fluid, or by decreasing the production of aqueous fluid.
Open Angle Glaucoma
Open-angle glaucoma is the most common type of glaucoma. It progresses slowly over time, is painless, and initially does not cause any vision changes or symptoms. Most people with open-angle glaucoma do not notice any change in their vision until the damage to their optic nerve is severe, and sometimes too late. This is why glaucoma is also called the “silent thief of sight.” Routine eye exams that include optic nerve examination, optic nerve imaging, and gonioscopy are key to identifying early signs of open-angle glaucoma and preventing blindness.
Angle Closure Glaucoma
Angle closure glaucoma is another type of glaucoma that can be diagnosed with optic nerve examination, optic nerve imaging, and gonioscopy. It can occur suddenly or gradually when the iris and pupil bulge forward to block the drainage angle partially or completely. A person with angle closure glaucoma will likely experience eye pain, headaches, visual halos redness, and nauseated. Once angle closure glaucoma is diagnosed it should be treated as a medical emergency to prevent permanent blindness. Microinvasive glaucoma surgery (MIGS) is not typically used to treat angle-closure glaucoma. However, MIGS may be an option if the angle is open enough after cataract removal, iridotomy, or iridoplasty.
Glaucoma Treatment
The goal in treating open angle glaucoma is to decrease IOP to prevent further damage to the optic nerve. First line treatment options include topical eyedrop medications, which can be effective at lowering IOP but may be difficult to administer. Many patients are unable to administer eye drops correctly and more than one-half of all patients with glaucoma struggle with medication adherence. This leads to glaucoma disease progression and increased loss of sight.
Microinvasive glaucoma surgery (MIGS) is a group of surgical procedures aimed to decrease IOP when medical therapy is ineffective. These micro-invasive procedures use microscopic-sized devices that result in smaller incisions, less surgical manipulation of the sclera and the conjunctiva, and result in shorter surgery times, less complications, and quicker recovery periods. The success and safety of MIGS in decreasing IOP is causing a shift that may lead to eye surgeons using MIGS earlier in the disease process.
- Research, Clinical Trials, and Evidence Summaries
Microinvasive glaucoma surgery (MIGS) has shown to be a significant advancement in glaucoma treatment, offering a safer and less invasive alternative to traditional surgery. Ongoing research and long-term studies will help to further refine the role of MIGS in glaucoma management.In 2020, the American Glaucoma Society issued a position paper on MIGS, supporting use of the procedures as a therapeutic option for patients with glaucoma.
Ahmed et al. (2022) published five-year post study results from the HORIZON trial, which assessed the long-term outcomes of a randomized controlled clinical trial to compare the results of cataract surgery (CS) combined with an intracanal micro-stent insertion to CS alone. A total of 556 eyes were randomized 2:1 with 369 eyes included in the CS and intracanal micro-stent insertion group and 187 eyes to the CS alone group. All participants had a diagnosis of an age-related cataract and mild to moderate primary open-angle glaucoma receiving 1 to 4 optic hypotensive medications. A five-year follow-up was completed on 80% of original participants. Results showed the CS with intracanal micro-stent insertion group had a higher number of eyes with IOP of 18 mmHg or less and a 20% reduction in IOP without medications when compared to the CS only group. Additionally, 66% of eyes in the CS with intracanal stent group were medication free compared to 46% in the CS only group. The authors concluded the combined CS with intracanal micro-stent procedure was safe, showed a reduction in IOP and medication use, and decreased the need for additional glaucoma surgeries compared to CS alone after five years post-procedure.
In 2023, the American Academy of Ophthalmology worked with Medicare contractors to ensure MIGS availability to patients who benefit from the procedures.
- U.S. Food & Drug Administration Information
VA generally only approves use of medical devices that have received at least Food & Drug Administration (FDA) clearance for 510(k) Premarket Notification. The FDA has determined these Class II devices are substantially equivalent (SE) to legally marketed predicate devices and may be marketed in the U.S.To search for devices that have received FDA 510(k) clearance or Premarket Approval (PMA), please visit the FDA Devices database.
- Medicare Coverage Determinations
Available Medicare national and local coverage determinations are listed below as a resource. VA and Medicare are governed by separate laws and regulations; thus, VA coverage determinations may be different.NCD Number Name Effective Date None N/A N/A LCD Number Name Original/Revision Effective Date DL37578 CGS Administrators, LLC Proposed L38223 Novitas Solutions, Inc 12/30/2019 L38233 First Coast Service Options, Inc 12/30/2019 L38299 Noridian Healthcare Solutions, LLC 11/17/2024 - NCD: National Coverage Determination
- LCD: Local Coverage Determination
- TRICARE Policy Manual
Available TRICARE coverage determinations are listed below as a resource. VA and TRICARE are governed by separate laws and regulations; thus, VA coverage determinations may be different.
- Health Care Procedural Coding Information
The following CPT®/HCPCS codes listed in this section are provided for informational purposes only. Inclusion or exclusion of a code does not constitute or imply VA coverage or provider reimbursement. The list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than CDI updates. Please refer to section II.a. in this document to review indications and clinical criteria for medical necessity.The following CPT codes are considered medically necessary/covered if the indications and clinical criteria outlined in section II.a. are met. Additional codes may also apply.
CPT Code Description 0671T Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more 0474T Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach into the supraciliary space 0253T Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space 0449T Insertion of aqueous drainage device without extraocular reservoir, internal approach, into the subconjunctival space, initial device 65820 Goniotomy 66989 Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (e.g., irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (e.g., iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (e.g., trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more 66991 Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (e.g., irrigation and aspiration or phacoemulsification); with insertion of intraocular (e.g., trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more CPT copyright 2024 American Medical Association. All rights reserved.
IV. Definitions
| Term | Definition |
|---|---|
| Ab interno | A procedure that is approached from inside the eye |
| Angle closure glaucoma | A type of glaucoma caused when the iris bulges, partially or completely blocking the drainage angle so fluid cannot flow out of the eye, resulting in rapid increased eye pressure |
| Aphakic | The absence of the lens within the eye due to surgical removal or congenital absence |
| Canaloplasty | Dilation and stenting of the Schlemm’s Canal to enhance aqueous fluid drainage |
| Endoscopic Diode Cyclophotocoagulation (ECP) | An ab interno procedure that destroys the ciliary body to decrease aqueous production and reduce intraocular pressure |
| Episcleral | A layer of clear tissue that covers the white part of the eye |
| Glaucoma | A group of eye diseases that can cause vision loss and blindness by damaging the optic nerve |
| Goniotomy | A surgical procedure that involves creating an opening in the eye’s drainage system to improve fluid drainage and reduce pressure |
| Intraocular pressure | Eye pressure or the fluid pressure of the eye |
| Irioplasty | A surgical procedure that uses a low energy laser to place burns on the iris and cause the iris to contract away from the anterior chamber angle |
| Iridotomy | A surgical procedure that uses a low energy laser to create a small opening in the iris to allow fluid to flow between the front and back chambers of the eye |
| Neovascular glaucoma | A type of secondary glaucoma where the angle of the eye is closed by new blood vessels and blocks aqueous fluid drainage |
| Open-angle glaucoma | The most common form of glaucoma, it occurs when the eye’s drainage canals become clogged over time |
| Phakic intraocular lenses | Phakic intraocular lenses are made of plastic, acrylic, and silicone and are implanted inside the eye without removing the natural human lens. Eyes that have not undergone cataract surgery (removal of the human crystalline lens) are termed “phakic eyes” |
| Pigmentary glaucoma | An eye condition where color pigment from the iris spreads to other parts of the eye and prevent aqueous fluid from draining |
| Pseudoexfoliative glaucoma | A systemic condition characterized by the deposition of a protein-like material within the anterior segment of the eye, most notably on the anterior lens capsule |
| Pseudophakic | An artificial lens, also known as an intraocular lens, that is implanted in an eye to replace the natural human clouded lens removed during cataract surgery |
| Refractory | Resistant to treatment or cure |
| Retrobulbar tumor | A tumor that originated from orbital tissue, which is outside the eye, often near the optic nerve |
| Schlemm’s canal | A circular lymphatic-like vessel in the eye that is responsible for draining aqueous fluid from the eye |
| Sturge-Weber syndrome | A rare, neurological disorder present at birth and characterized by a port-wine stain birthmark on the forehead and upper eyelid on one side of the face and often with increased intraocular pressure on the same side |
| Suprachoroidal space | A space between the sclera and choroid that aids maintaining intraocular pressure through a route alternative to the natural drainage route |
| Subconjunctival space | A space that is located superiorly above the cornea and under the conjunctiva and functions to distribute medications to several different parts of the eye |
| Trabecular meshwork | The spongy tissue located near the cornea through which aqueous fluid flows out of the eye |
| Trabeculectomy | A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye’s trabecular meshwork |
| Uveitic glaucoma | A type of glaucoma that is caused from an inflammation in the anterior portion of the eye |
| Uveoscleral | The drainage of ocular aqueous fluid from the anterior chamber into the anterior chamber angle rather than through the trabecular meshwork |
V. References
U.S. Food & Drug Administration Premarket Approval (PMA) Database. (n.d.). Retrieved July 25, 2024.
VI. CDI History/Revision Information
| Date | Summary of Updates |
|---|---|
| 08/28/2025 | Added language that VA follows FDA-approved indications for medical devices in “Clinical Determinations and Indications” section; Updated “Indications for Trabecular Meshwork Bypass by Tissue Excision (Trabeculotomy/Ab Interno Trabeculectomy)” section |
| 05/01/2025 | New CDI created describing medically necessary and not medically necessary indications |